NCT00109265View on ClinicalTrials.gov

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2001

Study Completion Date

October 31, 2002

Conditions
Breast Cancer
Interventions
DRUG

Erlotinib HCl (OSI-774)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY